A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer.
AffiliationCRC Department of Medical Oncology, Christie Hospital, Manchester, U.K.
MetadataShow full item record
AbstractA total of 45 patients with advanced non-small-cell lung cancer were treated with a combination of 1.5 g/m2 ifosfamide given on days 1-5 every 3 weeks for four courses with 3 million IU a2b-interferon (Intron A) given s.c. three times a week for 12 weeks. Nine objective responses were seen, including two complete responses (CRs) and seven partial responses (PRs). Haematological and non-haematological toxicities were generally mild and did not necessitate discontinuation of therapy.
CitationA phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer. 1991, 28 (2):142-4 Cancer Chemother Pharmacol
JournalCancer Chemotherapy and Pharmacology